Pulmonary embolism and deep vein thrombosis in COVID-19: a systematic review and meta-analysis
…, F Bompard, MP Revel, C Valle, A Gervaise, J Poissy… - Radiology, 2021 - pubs.rsna.org
Background The association of pulmonary embolism (PE) with deep vein thrombosis (DVT)
in patients with coronavirus disease 2019 (COVID-19) remains unclear, and the diagnostic …
in patients with coronavirus disease 2019 (COVID-19) remains unclear, and the diagnostic …
Distinct immune response in two MERS-CoV-infected patients: can we go from bench to bedside?
One year after the occurrence of the first case of infection by the Middle East Respiratory
Syndrome coronavirus (MERS-CoV) there is no clear consensus on the best treatment to …
Syndrome coronavirus (MERS-CoV) there is no clear consensus on the best treatment to …
Pulmonary embolism in patients with COVID-19: awareness of an increased prevalence
J Poissy, J Goutay, M Caplan, E Parmentier… - Circulation, 2020 - Am Heart Assoc
CORRESPONDENCE on admission and acute degradation of hemodynamic or respiratory
status. All CTPAs were performed with multibar computed tomography with no difference in …
status. All CTPAs were performed with multibar computed tomography with no difference in …
High prevalence of obesity in severe acute respiratory syndrome coronavirus‐2 (SARS‐CoV‐2) requiring invasive mechanical ventilation
A Simonnet, M Chetboun, J Poissy, V Raverdy… - …, 2020 - Wiley Online Library
Objective The COVID‐19 pandemic is rapidly spreading worldwide, notably in Europe and
North America where obesity is highly prevalent. The relation between obesity and severe …
North America where obesity is highly prevalent. The relation between obesity and severe …
[HTML][HTML] Remdesivir plus standard of care versus standard of care alone for the treatment of patients admitted to hospital with COVID-19 (DisCoVeRy): a phase 3 …
…, M Hites, N Peiffer-Smadja, J Poissy… - The Lancet infectious …, 2022 - thelancet.com
Background The antiviral efficacy of remdesivir against SARS-CoV-2 is still controversial.
We aimed to evaluate the clinical efficacy of remdesivir plus standard of care compared with …
We aimed to evaluate the clinical efficacy of remdesivir plus standard of care compared with …
Rationale and evidence for the use of new beta-lactam/beta-lactamase inhibitor combinations and cefiderocol in critically ill patients
…, S Kernéis, N Veluppillai, O Pajot, J Poissy… - Annals of Intensive …, 2023 - Springer
Background Healthcare-associated infections involving Gram-negative bacteria (GNB) with
difficult-to-treat resistance (DTR) phenotype are associated with impaired patient-centered …
difficult-to-treat resistance (DTR) phenotype are associated with impaired patient-centered …
[PDF][PDF] Characterization and treatment of SARS-CoV-2 in nasal and bronchial human airway epithelia
…, V Dulière, P Brun, S Constant, J Poissy… - Cell Reports …, 2020 - cell.com
In the current COVID-19 pandemic context, proposing and validating effective treatments
represents a major challenge. However, the scarcity of biologically relevant pre-clinical models …
represents a major challenge. However, the scarcity of biologically relevant pre-clinical models …
Autoantibodies neutralizing type I IFNs are present in~ 4% of uninfected individuals over 70 years old and account for~ 20% of COVID-19 deaths
…, CE Luyt, B Amador-Borrero, A Gaudet, J Poissy… - Science …, 2021 - science.org
Circulating autoantibodies (auto-Abs) neutralizing high concentrations (10 ng/ml; in plasma
diluted 1:10) of IFN-α and/or IFN-ω are found in about 10% of patients with critical COVID-19 …
diluted 1:10) of IFN-α and/or IFN-ω are found in about 10% of patients with critical COVID-19 …
The risk of COVID-19 death is much greater and age dependent with type I IFN autoantibodies
…, A Gaudet, J Poissy… - Proceedings of the …, 2022 - National Acad Sciences
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection fatality rate (IFR)
doubles with every 5 y of age from childhood onward. Circulating autoantibodies neutralizing …
doubles with every 5 y of age from childhood onward. Circulating autoantibodies neutralizing …
Modeling SARS-CoV-2 viral kinetics and association with mortality in hospitalized patients from the French COVID cohort
…, JF Timsit, E Faure, J Poissy… - Proceedings of the …, 2021 - National Acad Sciences
The characterization of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) viral
kinetics in hospitalized patients and its association with mortality is unknown. We analyzed …
kinetics in hospitalized patients and its association with mortality is unknown. We analyzed …
